Compare Amgen, Inc. (AMGN) vs Funko Inc (FNKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Funko Inc — how do they compare? Amgen, Inc. trades at $416.53 (market cap $224.14B), while Funko Inc trades at $5.94 (market cap $332.33M). The key difference: Amgen, Inc. is far larger — about 674.5× Funko Inc's market cap, and Amgen, Inc. pays a 2.43% dividend while Funko Inc pays none. Which is the better fit depends on your goals.
| AMGN | FNKO | |
|---|---|---|
Market Cap | $224.14B | $332.33M |
Sector | Health | Consumer Staples |
52-Week High | $417.20 | $6.35 |
52-Week Low | $271.18 | $2.65 |
Enterprise Value | $267.45B | $552.98M |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
FNKO trades at $5.86, down 5.33% on the day, amid mixed signals. The stock shows a bullish technical trend with strong moving average support, while oscillators are neutral. Fundamentally, revenue declined to $908.21M in 2025 with a net loss of $67.36M, though recent quarters have beaten EPS estimates. The company maintains a low P/S of 0.35 and appointed a new Chief Commercial Officer in August 2026 to drive growth.
Outlook is cautiously optimistic with improving EBITDA guidance and analyst buy ratings, but risks include persistent net losses, high debt levels, and competitive pressures in the collectibles market. The stock's valuation discount offers potential if profitability strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
